FGP
MRNA icon

Freestone Grove Partners’s Moderna MRNA Stock Holding History

Freestone Grove Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-14,272
Closed -$394K – 830
2025
Q2 		$394K Buy
+14,272
New +$376K ﹤0.01% 562

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Freestone Grove Partners's MRNA Position: Q3 2025 in Review

Freestone Grove Partners sold out of Moderna (MRNA) in Q3 2025, closing a stake of 14,272 shares — an estimated $394K sold.

Freestone Grove Partners first reported a position in MRNA in Q2 2025 and held it in 1 quarter. The position peaked at $394K in Q2 2025. 643 funds tracked by Wall St. Rank hold MRNA as of Q3 2025.

  • Freestone Grove Partners reported no remaining Moderna position as of Q3 2025 after selling out during the quarter.
  • Freestone Grove Partners sold 14,272 Moderna shares in Q3 2025, an estimated $394K.
  • Freestone Grove Partners first reported a position in Moderna in Q2 2025 and held it in 1 quarter.
  • Freestone Grove Partners's Moderna position peaked at $394K in Q2 2025.
  • 643 funds tracked by Wall St. Rank held Moderna as of Q3 2025.

Based on Freestone Grove Partners's 13F filing for Q3 2025, filed 14 Nov 2025.